Literature DB >> 9183665

Abnormal expression of Evi-1 gene in human leukemias.

S Ogawa1, K Mitani, M Kurokawa, Y Matsuo, J Minowada, J Inazawa, N Kamada, T Tsubota, Y Yazaki, H Hirai.   

Abstract

The human Evi-1 gene located on chromosome 3q26, encodes a zinc finger protein that functions as a transcription factor. It was frequently overexpressed in leukemias having 3q26 abnormalities such as t(3;3)(q21;q26) and inv(3)(q21 q26), and subjected to structural alteration in t(3;21)(q26;q22). In addition, recent studies indicated that several cases of leukemias without 3q26 abnormalities also expressed Evi-1 gene. In this study we present another case of structural alteration of Evi-1 gene in a case of inv(3)(q21 q26), in which Evi-1 was truncated and a shorter form of Evi-1 protein was expressed upon rearrangement of the gene. We also studied expression of the Evi-1 gene in a variety of leukemias by northern blot analysis. Evi-1 was overexpressed not only in leukemias with 3q26 abnormalities, but, in those without 3q26 abnormalities, especially in blast crisis of CML. Our result also supports an idea that Evi-1 is a relevant oncogene whose overexpression or structural changes might play a crucial role in development of human leukemias.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9183665

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  2 in total

1.  Imbalanced expression of polycistronic miRNA in acute myeloid leukemia.

Authors:  Ryutaro Kotaki; Hiroshi Higuchi; Daisuke Ogiya; Yasuhiro Katahira; Natsumi Kurosaki; Naoko Yukihira; Jun Ogata; Haruna Yamamoto; Syakira Mohamad Alba; Azran Azhim; Tatsuo Kitajima; Shigeaki Inoue; Kazuhiro Morishita; Koh Ono; Ryo Koyama-Nasu; Ai Kotani
Journal:  Int J Hematol       Date:  2017-08-22       Impact factor: 2.490

2.  A mutation in the Icsbp1 gene causes susceptibility to infection and a chronic myeloid leukemia-like syndrome in BXH-2 mice.

Authors:  Karine Turcotte; Susan Gauthier; Ashleigh Tuite; Alaka Mullick; Danielle Malo; Philippe Gros
Journal:  J Exp Med       Date:  2005-03-21       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.